DaVita Inc. (NYSE: DVA) stock surged on Tuesday after the company reported upbeat fourth-quarter earnings and fiscal 2026 guidance.
Earnings Summary
The kidney care provider reported adjusted earnings of $3.40 per share, beating the consensus of $3.16.
Sales came in at $3.62 billion, up 5.8% year over year, beating the consensus of $3.497 billion.
Revenue per treatment jumped from $410.59 to $422.60.
The quarter change was primarily driven by increases in average reimbursement rates and other normal fluctuations, as well as a slight improvement in mix and the seasonal impact of flu vaccines.
The year-to-date change was driven by the incorporation of phosphate binders into the ESRD Prospective Payment System bundle and an increase in average reimbursement rates from normal annual increases, including the Medicare base rate.
Total U.S. dialysis treatments for the fourth quarter …